Abstract Ibrutinib (PCI-32765), marketed under the trade name IMBRUVICA, is a first-in-
class irreversible inhibitor drug of Bruton tyrosine kinase (BTK). In the current research, its …

Purpose To report two cases of ibrutinib-related uveitis and review the literature to date.
Methods We report two cases of ibrutinib-related uveitis using CARE guidelines and review …

Introduction Bruton's tyrosine kinase (BTK) and interleukin (IL)-2 Inducible T-cell Kinase
(ITK) inhibitors have anti-inflammatory properties. We investigated the therapeutic effect of …

We report a case of alpelisib-induced uveitis. A 68-year-old female who had recently been
given alpelisib for metastatic breast cancer presented with a 2-week history of bilateral …

Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment paradigm of patients
with B-cell lymphomas. In recent years, studies of BTKi have demonstrated superior efficacy …

Purpose Ibrutinib is an irreversible Bruton's tyrosine kinase inhibitor that disrupts B-cell
receptor signalling. It is licensed for treatment of low-grade B-cell malignancies, including …

Introduction: Two cases of late presentation (> 5 years) of bilateral pseudophakic macula
edema related to oral tyrosine kinase inhibitors are described. These cases are the first of …

Ibrutinib is an oral, first‐line, targeted therapy for chronic lymphocytic leukemia (CLL).
Commonly reported adverse events are diarrhea, fatigue, and musculoskeletal pain, but …

A man in his mid-40s who had been recently started on alirocumab (a human monoclonal
antibody which inhibits proprotein convertase subtilisin/kexin type 9) due to his strong …

Introduction: Two cases of late presentation (> 5 years) of bilateral pseudophakic macula
edema related to oral tyrosine kinase inhibitors are described. These cases are the first of …